NO20075074L - Kinazolinon T-type-kalsiumkanalantagonister - Google Patents

Kinazolinon T-type-kalsiumkanalantagonister

Info

Publication number
NO20075074L
NO20075074L NO20075074A NO20075074A NO20075074L NO 20075074 L NO20075074 L NO 20075074L NO 20075074 A NO20075074 A NO 20075074A NO 20075074 A NO20075074 A NO 20075074A NO 20075074 L NO20075074 L NO 20075074L
Authority
NO
Norway
Prior art keywords
type calcium
kinazolinone
calcium channel
channel antagonists
compounds
Prior art date
Application number
NO20075074A
Other languages
English (en)
Inventor
James C Barrow
Rowena V Cube
Phung Le Ngo
Kenneth E Rittle
Zhiqiang Yang
Steven D Young
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20075074L publication Critical patent/NO20075074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører kinazolinonforbindelser som er antagonister av T-type-kalsiumkanaler, og som er anvendelige ved behandling eller forebygging av forstyrrelser og sykdommer hvori T-type-kalsiumkanaler er involvert. Oppfinnelsen vedrører også farmasøytiske blandinger inneholdende disse forbindelser og anvendelse av disse forbindelser og blandinger ved forebygging eller behandling av slike sykdommer hvori T-type-kalsiumkanaler er involvert.
NO20075074A 2005-03-09 2007-10-08 Kinazolinon T-type-kalsiumkanalantagonister NO20075074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65995405P 2005-03-09 2005-03-09
PCT/US2006/008177 WO2006098969A2 (en) 2005-03-09 2006-03-08 Quinazolinone t-type calcium channel antagonists

Publications (1)

Publication Number Publication Date
NO20075074L true NO20075074L (no) 2007-11-30

Family

ID=36992208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075074A NO20075074L (no) 2005-03-09 2007-10-08 Kinazolinon T-type-kalsiumkanalantagonister

Country Status (15)

Country Link
US (2) US7745452B2 (no)
EP (1) EP1858520B1 (no)
JP (1) JP2008533020A (no)
KR (1) KR20070110081A (no)
CN (1) CN101137380A (no)
AT (1) ATE527243T1 (no)
AU (1) AU2006223469A1 (no)
BR (1) BRPI0608343A2 (no)
CA (1) CA2600868A1 (no)
IL (1) IL185391A0 (no)
MX (1) MX2007010965A (no)
NO (1) NO20075074L (no)
RU (1) RU2007137266A (no)
WO (1) WO2006098969A2 (no)
ZA (1) ZA200706740B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858520B1 (en) * 2005-03-09 2011-10-05 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
AU2008275674A1 (en) * 2007-07-10 2009-01-15 Merck & Co., Inc. Quinazolinone T-type calcium channel antagonists
EP2209373B1 (en) * 2007-10-04 2012-05-23 Merck Sharp & Dohme Corp. N-substituted oxindoline derivatives as calcium channel blockers
US8314094B2 (en) * 2007-10-05 2012-11-20 Msd K.K Benzoxazinone derivative
EP2358684B8 (en) 2008-10-20 2014-10-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
FR2937552B1 (fr) * 2008-10-27 2011-05-06 Biocodex Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique
CN102791705B (zh) 2010-04-08 2016-08-03 美国政府(由卫生和人类服务部的部长所代表) 用于tsh受体的反向激动剂和中性拮抗剂
CN102906074A (zh) * 2010-05-24 2013-01-30 东亚荣养株式会社 稠合咪唑衍生物
AU2013324681B2 (en) * 2012-09-26 2017-08-10 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
IN2014CH00304A (no) * 2014-01-24 2015-09-04 Discovery Intermediates Pvt Ltd
US9145388B2 (en) 2014-02-19 2015-09-29 King Fahd University Of Petroleum And Minerals 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones
US9856250B2 (en) 2014-05-28 2018-01-02 Toa Eiyo Ltd. Substituted tropane derivatives
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
CN106749045B (zh) * 2017-03-03 2020-02-14 上海交通大学 一种d-氨基酸氧化酶抑制剂及其制法和应用
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
TWI879741B (zh) 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
KR20220066252A (ko) 2019-07-11 2022-05-24 프락시스 프리시젼 메디신즈, 인크. T형 칼슘 채널 조절제의 제형 및 이의 사용 방법
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
WO2025255502A1 (en) 2024-06-07 2025-12-11 Cavion, Inc. PYRIDYL AMIDE Cav3 CHANNEL MODULATORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
JP2002505288A (ja) * 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
JP3691341B2 (ja) * 2000-05-16 2005-09-07 日新製鋼株式会社 精密打抜き性に優れたオーステナイト系ステンレス鋼板
US20060003985A1 (en) * 2002-10-17 2006-01-05 Renger John J Enhancement of sleep with t-type calcium channel antagonists
EP1667685B1 (en) * 2003-09-23 2012-03-14 Merck Sharp & Dohme Corp. Quinazoline potassium channel inhibitors
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
EP1858520B1 (en) * 2005-03-09 2011-10-05 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
US20070162299A1 (en) * 2006-01-12 2007-07-12 Atsuko Ito Materials location system and selecting method of materials receiving locations

Also Published As

Publication number Publication date
EP1858520A4 (en) 2010-02-10
JP2008533020A (ja) 2008-08-21
US7745452B2 (en) 2010-06-29
CA2600868A1 (en) 2006-09-21
KR20070110081A (ko) 2007-11-15
MX2007010965A (es) 2007-09-19
RU2007137266A (ru) 2009-04-20
BRPI0608343A2 (pt) 2016-10-04
WO2006098969A2 (en) 2006-09-21
US20100261741A1 (en) 2010-10-14
AU2006223469A1 (en) 2006-09-21
US20080167329A1 (en) 2008-07-10
CN101137380A (zh) 2008-03-05
EP1858520A2 (en) 2007-11-28
EP1858520B1 (en) 2011-10-05
ATE527243T1 (de) 2011-10-15
WO2006098969A3 (en) 2007-03-01
IL185391A0 (en) 2008-02-09
ZA200706740B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
MX2010004530A (es) Antagonistas de los canales de calcio tipo t de heterociclo fenil amida.
WO2007120729A3 (en) Pyridyl amide t-type calcium channel antagonists
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
DE602007008434D1 (de) Rezeptoren
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
DE602004013563D1 (de) Rantagonisten
EP1606286A4 (en) BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application